Viemed Healthcare Management

Management criteria checks 3/4

Viemed Healthcare's CEO is Casey Hoyt, appointed in Dec 2017, has a tenure of 6.42 years. total yearly compensation is $2.51M, comprised of 20.3% salary and 79.7% bonuses, including company stock and options. directly owns 5.6% of the company’s shares, worth $18.14M. The average tenure of the management team and the board of directors is 6.4 years and 6.4 years respectively.

Key information

Casey Hoyt

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage	20.3%
CEO tenure	6.4yrs
CEO ownership	5.6%
Management average tenure	6.4yrs
Board average tenure	6.4yrs

Recent management updates

Recent updates

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Apr 11

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

Mar 07

CEO Compensation Analysis

How has Casey Hoyt's remuneration changed compared to Viemed Healthcare's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$509k	US$10m
Sep 30 2023	n/a	n/a	US$9m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	US$6m
Dec 31 2022	US$2m	US$470k	US$6m
Sep 30 2022	n/a	n/a	US$8m
Jun 30 2022	n/a	n/a	US$9m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	US$2m	US$470k	US$9m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$11m
Mar 31 2021	n/a	n/a	US$29m
Dec 31 2020	US$2m	US$441k	US$32m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$29m
Mar 31 2020	n/a	n/a	US$11m
Dec 31 2019	US$2m	US$425k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$9m
Dec 31 2018	US$2m	US$389k	US$10m
Sep 30 2018	n/a	n/a	US$7m
Jun 30 2018	n/a	n/a	US$9m
Mar 31 2018	n/a	n/a	US$8m
Dec 31 2017	US$1m	US$235k	US$8m

Compensation vs Market: Casey's total compensation ($USD2.51M) is about average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Casey's compensation has increased by more than 20% in the past year.

CEO

Casey Hoyt (46 yo)

6.4yrs

Tenure

US$2,512,214

Compensation

Mr. Casey Hoyt has been Director of Viemed Healthcare, Inc. since December 14, 2016 and Chief Executive Officer since December 2017. Mr. Hoyt served as Chief Executive Officer of Patient Home Monitoring Co...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Casey Hoyt	CEO & Director	6.4yrs	US$2.51m	5.6% $ 18.1m
Michael Moore	President	6.4yrs	US$1.95m	6.49% $ 21.0m
Trae Fitzgerald	Chief Financial Officer	6.4yrs	US$826.39k	0.17% $ 554.7k
William Zehnder	COO & Director	6.4yrs	US$1.94m	0.58% $ 1.9m
Jerome Cambre	Vice President of Sales	6.2yrs	US$805.30k	0.19% $ 621.7k
William Frazier	Chief Medical Officer & Director	6.4yrs	US$328.08k	0.17% $ 543.5k
Jeremy Trahan	EVP, Chief Legal Officer & Corporate Secretary	1.8yrs	no data	0.018% $ 57.9k
Patrick Eagan	General Counsel	no data	no data	0% $ 0
Michael Freeman	Chief Business Development Officer	1.8yrs	no data	no data

6.4yrs

Average Tenure

47yo

Average Age

Experienced Management: VMD's management team is seasoned and experienced (6.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Casey Hoyt	CEO & Director	7.4yrs	US$2.51m	5.6% $ 18.1m
William Zehnder	COO & Director	6.4yrs	US$1.94m	0.58% $ 1.9m
William Frazier	Chief Medical Officer & Director	6.4yrs	US$328.08k	0.17% $ 543.5k
Randolph Dobbs	Independent Chairman	6.4yrs	US$221.63k	0.24% $ 794.0k
Nitin Kaushal	Independent Director	6.4yrs	US$202.00k	0.30% $ 969.6k
Sabrina Heltz	Independent Director	3.5yrs	US$191.00k	0.098% $ 319.1k
Timothy Smokoff	Independent Director	6.4yrs	US$204.00k	0.21% $ 675.8k
Bruce Greenstein	Independent Director	5.8yrs	US$199.63k	0.17% $ 550.5k

6.4yrs

Average Tenure

57.5yo

Average Age

Experienced Board: VMD's board of directors are considered experienced (6.4 years average tenure).

Viemed Healthcare Management

Management criteria checks 3/4

Key information

Recent management updates

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

CEO & Director exercised options and sold US$182k worth of stock

Insufficient new directors

Viemed Announces Management Appointments

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Recent updates

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

When Should You Buy Viemed Healthcare, Inc. (NASDAQ:VMD)?

Consensus EPS estimates fall by 19%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

These 4 Measures Indicate That Viemed Healthcare (NASDAQ:VMD) Is Using Debt Safely

CEO & Director exercised options and sold US$182k worth of stock

Third quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Price target increased by 15% to US$15.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS misses analyst expectations

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

Insufficient new directors

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Viemed Healthcare: Comments On Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Healthcare Q2 2022 Earnings Preview

Viemed Announces Management Appointments

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare: New Bullish Trend Has Just Begun

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Viemed Healthcare, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Viemed Healthcare EPS misses by $0.01, revenue in-line

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day high: US$10.80

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance

Investor sentiment improved over the past week

New 90-day high: US$9.83

Strong Execution By Insider-Owners Ensures Viemed's Growth

Viemed Healthcare Announces Recent Publication of Non-Invasive Ventilation Study

New 90-day low: US$7.92

Viemed Healthcare, Inc. (TSX:VMD) acquired 5% stake in VeruStat, Inc for approximately $0.6 million.

Viemed Healthcare, Inc. Appoints Sabrina Heltz to the Board and to Serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board

Third quarter 2020 earnings released: EPS US$0.072

Revenue beats expectations, earnings disappoint

Viemed Healthcare EPS misses by $0.02, beats on revenue

Market pulls back on stock over the past week

New 90-day low: US$8.01

New 90-day low - US$8.92

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age